We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KemPharm Defends Abuse-Deterrence Evidence in Appeal over CRL for Opioid Apadaz
KemPharm Defends Abuse-Deterrence Evidence in Appeal over CRL for Opioid Apadaz
KemPharm has appealed the FDA’s complete response letter for its opioid Apadaz, contending that the company’s clinical evidence merits an approval with abuse-deterrent claims.